[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"normal-healthy-volunteer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:normal-healthy-volunteer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100603710","phase-1-a-research-study-to-evaluate-blx-7006-in-healthy-adults-100603710",false,"NCT07140055","A Research Study to Evaluate BLX-7006 in Healthy Adults","A Phase 1 Randomized, Double-blind, Placebo-controlled Single-ascending Dose and Multiple-ascending Dose (SAD and MAD) Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) BLX-7006 in Healthy Adults With a Body Mass Index (BMI) of 20 - 35 kg\u002Fm2","Inclusion Criteria:\n\n* Healthy males or females, 18-65 years, BMI 20-35 kilograms\u002Fmeter² (kg\u002Fm²), weight ≥50 kilograms (kg).\n* Normal or clinically acceptable labs, vital signs\n* HbA1c \\\u003C6.5%, non-fasting glucose 4.0-7.8 milimol\u002FLiter (mmol\u002FL)\n* Willing to follow contraception requirements, avoid alcohol, nicotine, and blood donation per protocol, and comply with all study visits and procedures.\n\nExclusion Criteria:\n\n* History of diabetes, clinically significant cardiovascular, hepatic, renal, gastrointestinal, psychiatric, or neurologic disease, or abnormal labs\u002FEchocardiograms (ECG) deemed clinically relevant.\n* Prior gastrointestinal (GI) surgery affecting absorption (e.g., gastric bypass) or chronic GI disorders.\n* History or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2); malignancy within 5 years (except treated basal cell or in situ cervical cancer).\n* History of severe allergic reactions, seizures, or psychiatric hospitalization; positive drug, alcohol, or cotinine test.\n* Use of prescription drugs, Over the counter (OTC) \u002Fherbal supplements\n* Participation in another clinical trial or blood donation within 30 days (or 5 half-lives of prior drug).\n* Any condition or history that may compromise safety, study conduct, or compliance, in the opinion of the Investigator.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},76,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection. This study will see if BLX-7006 is safe, how the body processes it, and whether food changes how it is absorbed. The main goal is to see if BLX-7006 is safe and well tolerated. Secondary objectives of the study will measure how BLX-7006 moves through the body after an oral dose, including how quickly it is absorbed, how long it stays in the blood, and how the body removes it. It will also look at how the drug affects the body by looking at markers of glucose metabolism.",[28,29],"Normal Healthy Volunteer","Safety After Oral Intake",[31,32,33,28],"Obesity","Type 2 Diabetes","Metabolic Disorders","NOT_YET_RECRUITING","2025-08-22",{"date":37,"type":38},"2025-08-24","ACTUAL",{"date":40,"type":22},"2025-09",{"date":42,"type":22},"2026-05",{"name":44,"class":45},"Biolexis Therapeutics","INDUSTRY"]